Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 127 clinical trials
Featured trial
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)

CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)

  • 340 views
  • 08 Nov, 2020
  • 1 location
Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer

breast cancer or ductal carcinoma in situ (DCIS). Subjects will be randomized to breast conserving surgery (BCS) utilizing either the BCL or wire localization (WL) to guide surgery.

  • 0 views
  • 29 Dec, 2021
  • 14 locations
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

carcinoma in situ (DCIS) patients, the aforementioned two studies included a proportional patients who had young age and negative estrogen receptor (ER) status tumor. Previous studies and our studies

breast tumor
cancer
radiotherapy to breast
mammogram
tamoxifen
  • 13 views
  • 14 Feb, 2022
  • 1 location
Management of Low-risk (Grade I and II) DCIS (LORD)

A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns slow-growing low-risk DCIS (grade I and II). This implies that many women might be unnecessarily

mastectomy
erbb2
digital mammography
cancer
HER2
  • 456 views
  • 25 Feb, 2022
  • 32 locations
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast (ROMANCE)

Following breast-conserving surgery (BCS) for localized ductal carcinoma in situ (DCIS) of the breast, whole-breast irradiation (WBRT) is a standard of care, reducing the absolute rate of in

progesterone receptor
growth factor
oophorectomy
treated by
lobular carcinoma in situ
  • 51 views
  • 09 Feb, 2022
  • 27 locations
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS (COMET)

is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AM approach does not yield inferior cancer or quality of life outcomes compared to surgery.

mastectomy
core needle biopsy
erbb2
endocrine therapy
cancer
  • 1335 views
  • 25 Feb, 2022
  • 118 locations
Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

This randomized phase III trial studies how well netupitant/palonosetron hydrochloride and dexamethasone with prochlorperazine or olanzapine work compared to netupitant/palonosetron hydrochloride and dexamethasone in improving chemotherapy-induced nausea and vomiting in patients with breast cancer. Antiemetic drugs, such as prochlorperazine and olanzapine, may help lessen nausea and vomiting in patients with …

trastuzumab
cyclophosphamide
cancer
methotrexate
herceptin
  • 16 views
  • 27 Feb, 2022
  • 15 locations
Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer

This trial studies the effect of an electronic health (eHealth) support program called PACK Health on patient reported health outcomes in patients with breast cancer. PACK Health monitors breast cancer patients' reported side effects and experience of care when receiving chemotherapy. Participating in the PACK Health coaching program may improve …

invasive breast cancer
ductal carcinoma
carcinoma in situ
carcinoma
breast cancer
  • 4 views
  • 14 Feb, 2022
  • 1 location
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

This phase II trial studies how well hypofractionated partial breast irradiation works in treating patients with early stage breast cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Treating only the part …

ct scan
partial breast irradiation
lobular carcinoma in situ
ductal carcinoma in situ
lobular carcinoma
  • 122 views
  • 25 Feb, 2022
  • 12 locations
Women Informed to Screen Depending on Measures of Risk (Wisdom Study) (WISDOM)

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but …

Accepts healthy volunteers
mammogram
breast cancer
cancer
  • 79 views
  • 26 Jan, 2022
  • 10 locations